{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:42:49Z","timestamp":1740148969066,"version":"3.37.3"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T00:00:00Z","timestamp":1724112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T00:00:00Z","timestamp":1724112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s12325-024-02951-5","type":"journal-article","created":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T09:02:44Z","timestamp":1724144564000},"page":"3771-3777","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Tapering and Sustained Remission of Thrombopoietin Receptor Agonists (TPO-RAs): Is it Time for Paediatric ITP?"],"prefix":"10.1007","volume":"41","author":[{"given":"Susana","family":"Marcos-Pe\u00f1a","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatriz","family":"Fern\u00e1ndez-Pernia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Drew","family":"Provan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2458-2554","authenticated-orcid":false,"given":"Tom\u00e1s Jos\u00e9","family":"Gonz\u00e1lez-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,20]]},"reference":[{"key":"2951_CR1","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1056\/NEJMoa1002625","volume":"363","author":"DJ Kuter","year":"2010","unstructured":"Kuter DJ, Rummel M, Boccia R, et al. Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med. 2010;363:1889\u201399.","journal-title":"N Engl J Med"},{"key":"2951_CR2","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/S0140-6736(10)60959-2","volume":"377","author":"G Cheng","year":"2011","unstructured":"Cheng G, Saleh MN, Marcher C, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet. 2011;377:393\u2013402.","journal-title":"Lancet"},{"key":"2951_CR3","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1182\/blood-2017-04-748707","volume":"130","author":"RSM Wong","year":"2017","unstructured":"Wong RSM, Saleh MN, Khelif A, et al. Safety and efficacy of long-term treatment of chronic\/persistent ITP with eltrombopag: final results of the EXTEND study. Blood. 2017;130:2527\u201336.","journal-title":"Blood"},{"key":"2951_CR4","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/bjh.15573","volume":"183","author":"W Jurczak","year":"2018","unstructured":"Jurczak W, Chojnowski K, Mayer J, et al. Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia. Br J Haematol. 2018;183:479\u201390.","journal-title":"Br J Haematol"},{"key":"2951_CR5","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1056\/NEJMoa054626","volume":"355","author":"JB Bussel","year":"2006","unstructured":"Bussel JB, Kuter DJ, George JN, et al. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med. 2006;355:1672\u201381.","journal-title":"N Engl J Med"},{"key":"2951_CR6","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1111\/bjh.13827","volume":"172","author":"A Newland","year":"2016","unstructured":"Newland A, Godeau B, Priego V, et al. Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study. Br J Haematol. 2016;172:262\u201373.","journal-title":"Br J Haematol"},{"key":"2951_CR7","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1111\/bjh.12888","volume":"165","author":"M Mah\u00e9vas","year":"2014","unstructured":"Mah\u00e9vas M, Fain O, Ebbo M, et al. The temporary use of thrombopoietin-receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia. Results of a French observational study. Br J Haematol. 2014;165:865\u20139.","journal-title":"Br J Haematol"},{"key":"2951_CR8","doi-asserted-by":"publisher","first-page":"E40","DOI":"10.1002\/ajh.23900","volume":"90","author":"TJ Gonz\u00e1lez-L\u00f3pez","year":"2015","unstructured":"Gonz\u00e1lez-L\u00f3pez TJ, Pascual C, \u00c1lvarez-Rom\u00e1n MT, et al. Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia. Am J Hematol. 2015;90:E40-43.","journal-title":"Am J Hematol"},{"key":"2951_CR9","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1111\/bjh.17334","volume":"193","author":"E Lucchini","year":"2021","unstructured":"Lucchini E, Palandri F, Volpetti S, et al. Eltrombopag second-line therapy in adult patients with primary immune thrombocytopenia in an attempt to achieve sustained remission off-treatment: results of a phase II, multicentre, prospective study. Br J Haematol. 2021;193:386\u201396.","journal-title":"Br J Haematol"},{"issue":"23","key":"2951_CR10","first-page":"2867","volume":"141","author":"S Guillet","year":"2023","unstructured":"Guillet S, Crickx E, Azzaoui I, et al. Gerfaud-Valentin M, Marolleau JP, Terriou L, et al.T, Roy-Peaud F, Robbins A, Lega JC, et al. Canoui-Poitrine F, Michel M, Godeau B, Mah\u00e9vas M. Prolonged response after TPO-RA discontinuation in primary ITP: results of a prospective multicenter study. Blood. 2023;141(23):2867\u201377.","journal-title":"Blood"},{"issue":"1","key":"2951_CR11","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1002\/ajh.27131","volume":"99","author":"N Cooper","year":"2024","unstructured":"Cooper N, Ghanima W, Vianelli N, et al. Sustained response off-treatment in eltrombopag-treated adult patients with ITP who are refractory or relapsed after first-line steroids: primary, final, and ad-hoc analyses of the phase II TAPER trial. Am J Hematol. 2024;99(1):57\u201367.","journal-title":"Am J Hematol"},{"issue":"2","key":"2951_CR12","doi-asserted-by":"publisher","first-page":"165","DOI":"10.12701\/yujm.2020.00493","volume":"38","author":"HJ Lim","year":"2021","unstructured":"Lim HJ, Lim YT, Hah JO, Lee JM. Delayed treatment-free response after romiplostim discontinuation in pediatric chronic immune thrombocytopenia. Yeungnam Univ J Med. 2021;38(2):165\u20138.","journal-title":"Yeungnam Univ J Med"},{"issue":"2","key":"2951_CR13","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1111\/bjh.18842","volume":"202","author":"Z Wang","year":"2023","unstructured":"Wang Z, Wang L, Liu Y, et al. Sustained response off treatment in eltrombopag for children with persistent\/chronic primary immune thrombocytopenia: a multicentre observational retrospective study in China. Br J Haematol. 2023;202(2):422\u20138.","journal-title":"Br J Haematol"},{"key":"2951_CR14","doi-asserted-by":"publisher","unstructured":"Neunert CE. Management of newly diagnosed immune thrombocytopenia: can we change outcomes? Blood Adv. 2017;1(24):2295\u20132301. https:\/\/doi.org\/10.1182\/bloodadvances.2017009860. Erratum in: Blood Adv. 2018;2(15):1817.","DOI":"10.1182\/bloodadvances.2017009860"},{"issue":"22","key":"2951_CR15","doi-asserted-by":"publisher","first-page":"4457","DOI":"10.1182\/blood-2012-12-466375","volume":"121","author":"CE Neunert","year":"2013","unstructured":"Neunert CE, Buchanan GR, Imbach P, et al. Bleeding manifestations and management of children with persistent and chronic immune thrombocytopenia: data from the Intercontinental Cooperative ITP Study Group (ICIS). Blood. 2013;121(22):4457\u201362.","journal-title":"Blood"},{"issue":"5","key":"2951_CR16","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1097\/MOH.0000000000000270","volume":"23","author":"A Cuker","year":"2016","unstructured":"Cuker A, Cines DB, Neunert CE. Controversies in the treatment of immune thrombocytopenia. Curr Opin Hematol. 2016;23(5):479\u201385.","journal-title":"Curr Opin Hematol"},{"key":"2951_CR17","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.clpt.2004.08.010","volume":"76","author":"B Wang","year":"2004","unstructured":"Wang B, Nichol JL, Sullivan JT. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther. 2004;76:628\u201338.","journal-title":"Clin Pharmacol Ther"},{"key":"2951_CR18","doi-asserted-by":"publisher","first-page":"4639","DOI":"10.1182\/blood-2010-04-281717","volume":"116","author":"W Bao","year":"2010","unstructured":"Bao W, Bussel JB, Heck S, et al. Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents. Blood. 2010;116:4639\u201345.","journal-title":"Blood"},{"issue":"Suppl 1","key":"2951_CR19","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1053\/j.seminhematol.2016.04.010","volume":"53","author":"A Schifferli","year":"2016","unstructured":"Schifferli A, K\u00fchne T. Thrombopoietin receptor agonists: a new immune modulatory strategy in immune thrombocytopenia? Semin Hematol. 2016;53(Suppl 1):S31\u20134.","journal-title":"Semin Hematol"},{"key":"2951_CR20","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1182\/blood-2016-01-690727","volume":"128","author":"XG Liu","year":"2016","unstructured":"Liu XG, Liu S, Feng Q, et al. Thrombopoietin receptor agonists shift the balance of Fc\u03b3 receptors toward inhibitory receptor IIb on monocytes in ITP. Blood. 2016;128:852\u201361.","journal-title":"Blood"},{"key":"2951_CR21","doi-asserted-by":"publisher","unstructured":"Mingot-Castellano ME, Rom\u00e1n MT\u00c1, Fern\u00e1ndez Fuertes LF, et al. Management of adult patients with primary immune thrombocytopenia (ITP) in clinical practice: a consensus approach of the Spanish ITP Expert Group. Adv Hematol. 2019; https:\/\/doi.org\/10.1155\/2019\/4621416","DOI":"10.1155\/2019\/4621416"},{"issue":"11","key":"2951_CR22","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1182\/blood-2008-07-162503","volume":"113","author":"F Rodeghiero","year":"2009","unstructured":"Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386\u201393.","journal-title":"Blood"},{"issue":"12","key":"2951_CR23","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.3324\/haematol.2011.050799","volume":"96","author":"T K\u00fchne","year":"2011","unstructured":"K\u00fchne T, Berchtold W, Michaels LA, et al. Newly diagnosed immune thrombocytopenia in children and adults: a comparative prospective observational registry of the Intercontinental Cooperative Immune Thrombocytopenia Study Group. Haematologica. 2011;96(12):1831\u20137.","journal-title":"Haematologica"},{"key":"2951_CR24","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023012541","author":"CE Neunert","year":"2024","unstructured":"Neunert CE, Arnold DM, Grace RF, K\u00fchne T, McCrae KR, Terrell DR. 2022 review of the 2019 American Society of Hematology guidelines on immune thrombocytopenia. Blood Adv. 2024. https:\/\/doi.org\/10.1182\/bloodadvances.2023012541.","journal-title":"Blood Adv"},{"key":"2951_CR25","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1182\/asheducation-2018.1.405","volume":"1","author":"JM Despotovic","year":"2018","unstructured":"Despotovic JM, Grimes AB. Pediatric ITP: is it different from adult ITP? Hematology Am Soc Hematol Educ Program. 2018;1:405\u201311.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"6","key":"2951_CR26","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1002\/ajh.26900","volume":"98","author":"T Pincez","year":"2023","unstructured":"Pincez T, Fernandes H, Pasquet M, et al. Impact of age at diagnosis, sex, and immunopathological manifestations in 886 patients with pediatric chronic immune thrombocytopenia. Am J Hematol. 2023;98(6):857\u201368.","journal-title":"Am J Hematol"},{"issue":"3","key":"2951_CR27","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1111\/bjh.19253","volume":"204","author":"Z Wang","year":"2024","unstructured":"Wang Z, Wang N, Juntao O, et al. Long-term eltrombopag in children with chronic immune thrombocytopenia: a single-centre extended real-life observational study in China. Br J Haematol. 2024;204(3):1017\u201323.","journal-title":"Br J Haematol"},{"issue":"5","key":"2951_CR28","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1111\/bjh.19342","volume":"204","author":"Z Wang","year":"2024","unstructured":"Wang Z, Zhang A, Xu Z, et al. Efficacy and safety of avatrombopag in Chinese children with persistent and chronic primary immune thrombocytopenia: a multicentre observational retrospective study in China. Br J Haematol. 2024;204(5):1958\u201365.","journal-title":"Br J Haematol"},{"issue":"6","key":"2951_CR29","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29023","volume":"68","author":"KA Shimano","year":"2021","unstructured":"Shimano KA, Neunert C, Bussel JB, et al. Quality of life is an important indication for second-line treatment in children with immune thrombocytopenia. Pediatr Blood Cancer. 2021;68(6): e29023.","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"2951_CR30","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1159\/000510676","volume":"144","author":"N Cooper","year":"2021","unstructured":"Cooper N, Hill QA, Grainger J, et al. Tapering and discontinuation of thrombopoietin receptor agonist therapy in patients with immune thrombocytopenia: results from a modified Delphi panel. Acta Haematol. 2021;144(4):418\u201326.","journal-title":"Acta Haematol"},{"key":"2951_CR31","doi-asserted-by":"publisher","first-page":"204062072110483","DOI":"10.1177\/20406207211048361","volume":"12","author":"M Carpenedo","year":"2021","unstructured":"Carpenedo M, Baldacci E, Barat\u00e8 C, et al. Second-line administration of thrombopoietin receptor agonists in immune thrombocytopenia: Italian Delphi-based consensus recommendations. Ther Adv Hematol. 2021;12:20406207211048360.","journal-title":"Ther Adv Hematol"},{"issue":"1","key":"2951_CR32","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/bjh.19082","volume":"203","author":"TJ Gonz\u00e1lez-L\u00f3pez","year":"2023","unstructured":"Gonz\u00e1lez-L\u00f3pez TJ, Schifferli A. Early immunomodulation in immune thrombocytopenia\u2014A report of the ICIS meeting in Lenzerheide, Switzerland 2022. Br J Haematol. 2023;203(1):101\u201311.","journal-title":"Br J Haematol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02951-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-02951-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02951-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T16:26:33Z","timestamp":1726244793000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-02951-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,20]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["2951"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-02951-5","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"type":"print","value":"0741-238X"},{"type":"electronic","value":"1865-8652"}],"subject":[],"published":{"date-parts":[[2024,8,20]]},"assertion":[{"value":"4 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Tom\u00e1s Jos\u00e9 Gonz\u00e1lez-L\u00f3pez has received research grants from Amgen and Novartis and speaker honoraria from Amgen, Novartis, Sobi, Grifols and Argenx. Drew Provan acknowledges the following competing interests: research support from Amgen, and Novartis; honoraria from Amgen, Novartis, SOBI, UCB, and Argenx; consultancies with UCB, MedImmune, Ono, SOBI, Argenx, and Takeda. Susana Marcos Pe\u00f1a and Beatriz Fern\u00e1ndez-Pernia declare no competing financial interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}